Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Xeomin for Excessive Drooling

Merz North America news release; 2018 Jul 3

Merz North America has announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients. Xeomin is the first and only neurotoxin with this approved indication in the US. Merz North America is headquartered in Raleigh, NC.

Sialorrhea is a common symptom among patients who suffer from neurological disorders including Parkinson disease, amyotrophic lateral sclerosis (ALS), cerebral palsy (CP), or who have experienced a stroke. The condition can occur from difficulty retaining saliva inside the mouth, issues with swallowing and from problems controlling facial muscles.

Indications: Xeomin is an acetylcholine release inhibitor and neuromuscular blocking

agent indicated for the treatment or improvement of adult patients with chronic sialorrhea.

Dosage/administration: For chronic sialorrhea, the recommended total dose is 100 units per treatment session consisting of 30 units per parotid gland and 20 units per submandibular gland, no sooner than every 16 weeks.

Adverse reactions: The most commonly observed adverse reactions in patients with chronic sialorrhea, at rates specified below and greater than placebo, are tooth extraction, dry mouth,

diarrhea, and hypertension.

Citation:

FDA approves Xeomin (incobotulinumtoxinA) for adult patients with sialorrhea. [news release]. Raleigh, NC: Merz North America. July 3, 2018. https://www.businesswire.com/news/home/20180703005550/en/FDA-Approves-XEOMIN%C2%AE-incobotulinumtoxinA-Adult-Patients-Sialorrhea. Accessed July 10, 2018.

This Week's Must Reads

Stroke Care Comparison of Asian Americans and Whites, JAMA Neurology; ePub 2019 Jan 22; Song, Liang, et al

Aerobic Exercise Can Improve Executive Functioning , Neurology; 2019 Jan 15; Blumenthal, et al

Episodic Memory Decline is Neurodegenerative Marker, Neurology; ePub 2019 Jan 23; Wilson, Yang, et al

Serum Troponin Level Marker for Visceral Infarcts , J Stroke Cerebrovasc Dis; ePub 2019 Jan 18; Azher, et al

Urine Sodium-to-Potassium Ratio Predicts Stroke, Stroke; ePub 2019 Jan 21; Averill, Young, et al

Must Reads in FDA Actions

FDA Approves Inbrija for PD OFF Episodes, Acorda Therapeutics news release; 2018 Dec 21

FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23